XML 28 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Revenues
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenue, Net
The Company’s product revenue is derived from the sales of its commercial products in Greater China. The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended March 31,
20252024
Product revenue - gross112,333 93,112 
Less: Rebates and sales returns(6,683)(5,963)
Product revenue - net105,650 87,149 
Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of product revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended March 31,
20252024
ZEJULA49,529 45,501 
VYVGART / VYVGART Hytrulo18,105 13,162 
NUZYRA15,118 9,913 
OPTUNE11,363 12,480 
QINLOCK8,509 6,093 
XACDURO1,117 — 
AUGTYRO1,626 — 
Other (i)283 — 
Product revenue - net105,650 87,149 
(i)Other includes product candidates sold in patient programs prior to commercialization.
Collaboration Revenue
Collaboration revenue was $0.8 million in the first quarter of 2025 and related to promotional activities in mainland China. We had no such collaboration revenue in the first quarter of 2024.